The DOI matches its Crossref record; 229 of the 229 references it cites were found in a registry or an index.
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Open accessAbstract
Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling mediates almost all immune regulatory processes, including those that are involved in tumor cell recognition and tumor-driven immune escape. Antitumor immune responses are largely driven by STAT1 and STAT2 induction of type I and II interferons (IFNs) and the downstream programs IFNs potentiate. Conversely, STAT3 has been widely linked to cancer cell survival, immunosuppression, and sustained inflammation in the tumor microenvironment. The discovery of JAK-STAT cross-regulatory mechanisms, post-translational control, and non-canonical signal transduction has added a new level of complexity to JAK-STAT governance over tumor initiation and progression. Endeavors to better understand the vast effects of JAK-STAT signaling on antitumor immunity have unearthed a wide range of targets, including oncogenes, miRNAs, and other co-regulatory factors, which direct specific phenotypical outcomes subsequent to JAK-STAT stimulation. Yet, the rapidly expanding field of therapeutic developments aimed to resolve JAK-STAT aberrations commonly reported in a multitude of cancers has been marred by off-target effects. Here, we discuss JAK-STAT biology in the context of immunity and cancer, the consequences of pathway perturbations and current therapeutic interventions, to provide insight and consideration for future targeting innovations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kaewpiboon, C., Srisuttee, R., Malilas, W., Moon, J., Oh, S., Jeong, H. G., Johnston, R. N., Assavalapsakul, W., & Chung, Y. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2949 · Cited by 35
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
The regulation of IL-10 production by immune cells
Saraiva, M., & O'Garra, A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2711 · Cited by 3,164
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
IRF-7 is the master regulator of type-I interferon-dependent immune responses
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N., Ohba, Y., Takaoka, A., Yoshida, N., et al. (2005) · Nature · doi:10.1038/nature03464 · Cited by 2,245
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Stat6 Is Required for Mediating Responses to IL-4 and for the Development of Th2 Cells
Kaplan, M. H., Schindler, U., Smiley, S. T., & Grusby, M. J. (1996) · Immunity · doi:10.1016/s1074-7613(00)80439-2 · Cited by 1,628
gp 130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES
Taga, T., & Kishimoto, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.797 · Cited by 1,461
Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors
Honda, K., Takaoka, A., & Taniguchi, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.009 · Cited by 1,393
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
JAK-STAT Signaling: From Interferons to Cytokines
Schindler, C., Levy, D. E., & Decker, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700016200 · Cited by 1,258
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Rosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 2×
“transendothelial migration of tumor cells [107], the recruitment of neutrophils and macrophages into the TME through endothelial cell secretion of monocyte chemoattractant protein-1 (MCP-1) [108], M2 polarization of macrophages, inhibition of DC activation, and Treg differentiation [109].”
BackgroundKolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J., & Murali-Krishna, K. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050821 · Cited by 965
Hu, X., & Ivashkiv, L. B. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.002 · Cited by 928
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Self-citationRodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C. F., Yin, L., Pennica, D., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81166-6 · Cited by 853
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829
Lütticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., et al. (1994) · Science · doi:10.1126/science.8272872 · Cited by 814
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
Koskela, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 777
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Jiang, S., Zhang, H.-W., Lu, M.-H., He, X.-H., Li, Y., Gu, H., Liu, M.-F., & Wang, E.-D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4250 · Cited by 679
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.233 · Cited by 637
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., & Kouzarides, T. (2009) · Nature · doi:10.1038/nature08448 · Cited by 622
Weichselbaum, R. R., Ishwaran, H., Yoon, T., Nuyten, D. S. A., Baker, S. W., Khodarev, N., Su, A. W., Shaikh, A. Y., Roach, P., Kreike, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809242105 · Cited by 615
Constitutive activation of STAT 3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611
Nguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X.-Q., Liew, F. Y., Caligiuri, M. A., Durbin, J. E., & Biron, C. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4279 · Cited by 610
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Prognostic value of intratumoral natural killer cells in gastric carcinoma
Ishigami, S., Natsugoe, S., Tokuda, K., Nakajo, A., Che, X., Iwashige, H., Aridome, K., Hokita, S., & Aikou, T. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000201)88:3<577::aid-cncr13>3.0.co;2-v · Cited by 586
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Nonredundant roles for Stat5a/b in directly regulating Foxp3
Yao, Z., Kanno, Y., Kerenyi, M., Stephens, G., Durant, L., Watford, W. T., Laurence, A., Robinson, G. W., Shevach, E. M., Moriggl, R., et al. (2007) · Blood · doi:10.1182/blood-2006-11-055756 · Cited by 575
Signaling by IL‐12 and IL‐23 and the immunoregulatory roles of STAT4
Watford, W. T., Hissong, B. D., Bream, J. H., Kanno, Y., Muul, L., & O'Shea, J. J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00211.x · Cited by 572
CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling
Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G., Griffiths, E., Krawczyk, C., Richardson, C. D., Aitken, K., et al. (2001) · Nature · doi:10.1038/35053086 · Cited by 562
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
Stat1-dependent and -independent pathways in IFN-γ-dependent signaling
Ramana, C. V., Gil, M. P., Schreiber, R. D., & Stark, G. R. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02118-4 · Cited by 555
Positive feedback regulation of type I IFN genes by the IFN‐inducible transcription factor IRF‐7
Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., & Tanaka, N. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01514-2 · Cited by 553
Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Bai, D., Ueno, L., & Vogt, P. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24748 · Cited by 529
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526
Activation of the STAT Signaling Pathway Can Cause Expression of Caspase 1 and Apoptosis
Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A., & Fu, X.-Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5328 · Cited by 521
Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
Bhat, P., Leggatt, G., Waterhouse, N., & Frazer, I. H. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.67 · Cited by 515
Direct Effects of Type I Interferons on Cells of the Immune System
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 503
Fu, X. Y., Kessler, D. S., Veals, S. A., Levy, D. E., & Darnell, J. E. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8555 · Cited by 489
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N. E., Samarajiwa, S. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2830 · Cited by 487
Self-citationThe paradoxical role of IL-10 in immunity and cancer
Mannino, M. H., Zhu, Z., Xiao, H., Bai, Q., Wakefield, M. R., & Fang, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.009 · Cited by 473
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470 · cited 11×
“(c) IFNAR1/2 signaling through TYK2 and JAK1 can trigger the activation of the NFκB pathway through phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), and TNF receptor-associated factors (TRAFs) that act through IKKa and IKKb to drive NFκB induction of genes associated with survival and cell proliferation.”
BackgroundInfluentialInterleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
GAS Elements: A Few Nucleotides with a Major Impact on Cytokine-Induced Gene Expression
DECKER, T., KOVARIK, P., & MEINKE, A. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.121 · Cited by 437
Gan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., & Guo, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0122-2 · Cited by 426
Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity
Liu, B., Qu, L., & Yan, S. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0260-7 · Cited by 415
De Larco, J. E., Wuertz, B. R. K., & Furcht, L. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0760 · Cited by 412
Wrangle, J. M., Velcheti, V., Patel, M. R., Garrett-Mayer, E., Hill, E. G., Ravenel, J. G., Miller, J. S., Farhad, M., Anderton, K., Lindsey, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30148-7 · Cited by 412
Müller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J. E., Stark, G. R., & Kerr, I. M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06106.x · Cited by 411
NF‐κB: roles and regulation in different CD 4+ T‐cell subsets
Oh, H., & Ghosh, S. (2013) · Immunological Reviews · doi:10.1111/imr.12033 · Cited by 408
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. (2001) · International Immunology · doi:10.1093/intimm/13.4.459 · Cited by 379
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J. (2008) · International Immunology · doi:10.1093/intimm/dxn028 · Cited by 377
Type I interferon response and innate immune sensing of cancer
Fuertes, M. B., Woo, S.-R., Burnett, B., Fu, Y.-X., & Gajewski, T. F. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.004 · Cited by 375
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
A Breakthrough: Macrophage-Directed Cancer Immunotherapy
Mills, C. D., Lenz, L. L., & Harris, R. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1737 · Cited by 356
Regulation of the type I IFN induction: a current view
Honda, K., Yanai, H., Takaoka, A., & Taniguchi, T. (2005) · International Immunology · doi:10.1093/intimm/dxh318 · Cited by 348
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function
Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C. F., Scott, B., Schreiber, R. D., Hertzog, P., & Smyth, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7540 · Cited by 339
TLR agonists: our best frenemy in cancer immunotherapy
Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339
Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J., Barve, M., Daniels, G. A., Wong, D. J., Schmidt, E. V., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0280 · Cited by 337
Zhao, J.-J., Lin, J., Lwin, T., Yang, H., Guo, J., Kong, W., Dessureault, S., Moscinski, L. C., Rezania, D., Dalton, W. S., et al. (2010) · Blood · doi:10.1182/blood-2009-09-243147 · Cited by 335
Khodarev, N. N., Beckett, M., Labay, E., Darga, T., Roizman, B., & Weichselbaum, R. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308102100 · Cited by 326
NK Cells, MHC Class I Molecules and the Missing Self
Kärre, K. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2002.01053.x · Cited by 325
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Oft, M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0214 · Cited by 322 · cited 1×
“Highly expressed by Th17 cells, myeloid DCs, and TAMs [111] following the context-dependent activation of STAT3, auxiliary STATs, and extracellular signal-regulated kinase (ERK) pathways [111], the IL-10 family of cytokines have been reported to block cytotoxic T cell function through the inhibition of APCs [111] and…”
BackgroundMichalska, A., Blaszczyk, K., Wesoly, J., & Bluyssen, H. A. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01135 · Cited by 322
Roles of the NF- B Pathway in Lymphocyte Development and Function
Gerondakis, S., & Siebenlist, U. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000182 · Cited by 320
Alternative Activation of STAT1 and STAT3 in Response to Interferon-γ
Qing, Y., & Stark, G. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406413200 · Cited by 316
Kessler, D. S., Veals, S. A., Fu, X. Y., & Levy, D. E. (1990) · Genes & Development · doi:10.1101/gad.4.10.1753 · Cited by 312
Kim, G.-Y., Kim, K.-H., Lee, S.-H., Yoon, M.-S., Lee, H.-J., Moon, D.-O., Lee, C.-M., Ahn, S.-C., Park, Y. C., & Park, Y.-M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.8116 · Cited by 306
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition
Groner, B., & von Manstein, V. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.033 · Cited by 306
Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes
Cheon, H., & Stark, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903487106 · Cited by 305
Masjedi, A., Hashemi, V., Hojjat-Farsangi, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., & Jadidi-Niaragh, F. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.177 · Cited by 303 · cited 13×
“In the TME, IL-6 trans-signaling promotes stable binding of GP130 and a soluble form of the IL-6 receptor (sIL-6R) to IL-6 [106].”
BackgroundInfluentialInterferon α/β-mediated inhibition and promotion of interferon γ: STAT1 resolves a paradox
Nguyen, K. B., Cousens, L. P., Doughty, L. A., Pien, G. C., Durbin, J. E., & Biron, C. A. (2000) · Nature Immunology · doi:10.1038/76940 · Cited by 303
Hurwitz, H. I., Uppal, N., Wagner, S. A., Bendell, J. C., Beck, J. T., Wade, S. M., Nemunaitis, J. J., Stella, P. J., Pipas, J. M., Wainberg, Z. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4578 · Cited by 292
IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1
Hsu, P., Santner-Nanan, B., Hu, M., Skarratt, K., Lee, C. H., Stormon, M., Wong, M., Fuller, S. J., & Nanan, R. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402898 · Cited by 286
Karantanos, T., Evans, C. P., Tombal, B., Thompson, T. C., Montironi, R., & Isaacs, W. B. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.049 · Cited by 285
Xu, X., Fu, X.-Y., PLATE, J. M. D., & Chong, A. S. (1998) · PubMed · Cited by 283
Carlsten, M., Norell, H., Bryceson, Y. T., Poschke, I., Schedvins, K., Ljunggren, H.-G., Kiessling, R., & Malmberg, K.-J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901226 · Cited by 283
PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity
Liu, B., Mink, S., Wong, K. A., Stein, N., Getman, C., Dempsey, P. W., Wu, H., & Shuai, K. (2004) · Nature Immunology · doi:10.1038/ni1104 · Cited by 271
Stat1 Depends on Transcriptional Synergy with Sp1
Look, D. C., Pelletier, M. R., Tidwell, R. M., Roswit, W. T., & Holtzman, M. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.51.30264 · Cited by 268
The good and the bad faces of STAT1 in solid tumours
Meissl, K., Macho-Maschler, S., Müller, M., & Strobl, B. (2017) · Cytokine · doi:10.1016/j.cyto.2015.11.011 · Cited by 264
IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway
Fulda, S., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205255 · Cited by 260
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256
STAT1 and STAT3 in tumorigenesis: A matter of balance
Avalle, L., Pensa, S., Regis, G., Novelli, F., & Poli, V. (2012) · JAK-STAT · doi:10.4161/jkst.20045 · Cited by 255
S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites
Deng, J., Liu, Y., Lee, H., Herrmann, A., Zhang, W., Zhang, C., Shen, S., Priceman, S. J., Kujawski, M., Pal, S. K., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.039 · Cited by 252
Reilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245
NK cells regulating T cell responses: mechanisms and outcome
Crouse, J., Xu, H. C., Lang, P. A., & Oxenius, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.11.001 · Cited by 242
Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T., & Bentires-Alj, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.023 · Cited by 240
The molecular basis for differential type I interferon signaling
Schreiber, G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.774562 · Cited by 240
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., & O'Shea, J. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.008 · Cited by 233
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Smith, M., García-Martínez, E., Pitter, M. R., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526250 · Cited by 232
Regulation of cytokine signaling pathways by PIAS proteins
Shuai, K. (2006) · Cell Research · doi:10.1038/sj.cr.7310027 · Cited by 221
STAT3 in Cancer—Friend or Foe?
Zhang, H.-F., & Lai, R. (2014) · Cancers · doi:10.3390/cancers6031408 · Cited by 219
Distinct Requirements for IFNs and STAT1 in NK Cell Function
Lee, C.-K., Rao, D. T., Gertner, R., Gimeno, R., Frey, A. B., & Levy, D. E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.3571 · Cited by 217
JAK-STAT signaling in cancer: From cytokines to non-coding genome
Pencik, J., Pham, H. T. T., Schmoellerl, J., Javaheri, T., Schlederer, M., Culig, Z., Merkel, O., Moriggl, R., Grebien, F., & Kenner, L. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.017 · Cited by 215
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Margolin, K., Morishima, C., Velcheti, V., Miller, J. S., Lee, S. M., Silk, A. W., Holtan, S. G., Lacroix, A. M., Fling, S. P., Kaiser, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0945 · Cited by 208
Khodarev, N. N., Roizman, B., & Weichselbaum, R. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3225 · Cited by 203
Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers
Jeong, E. G., Kim, M. S., Nam, H. K., Min, C. K., Lee, S., Chung, Y. J., Yoo, N. J., & Lee, S. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4839 · Cited by 201
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance
Palmer, D. C., Guittard, G. C., Franco, Z., Crompton, J. G., Eil, R. L., Patel, S. J., Ji, Y., Van Panhuys, N., Klebanoff, C. A., Sukumar, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150304 · Cited by 200
Functional Crosstalk between Type I and II Interferon through the Regulated Expression of STAT1
Gough, D. J., Messina, N. L., Hii, L., Gould, J. A., Sabapathy, K., Robertson, A. P. S., Trapani, J. A., Levy, D. E., Hertzog, P. J., Clarke, C. J. P., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000361 · Cited by 193
IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
Lo, C.-W., Chen, M.-W., Hsiao, M., Wang, S., Chen, C.-A., Hsiao, S.-M., Chang, J.-S., Lai, T.-C., Rose-John, S., Kuo, M.-L., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1496 · Cited by 193
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
Zhao, M., Guo, W., Wu, Y., Yang, C., Zhong, L., Deng, G., Zhu, Y., Liu, W., Gu, Y., Lu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.08.009 · Cited by 190
Mandal, M., Powers, S. E., Maienschein-Cline, M., Bartom, E. T., Hamel, K. M., Kee, B. L., Dinner, A. R., & Clark, M. R. (2011) · Nature Immunology · doi:10.1038/ni.2136 · Cited by 190
Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy
Shafabakhsh, R., Pourhanifeh, M. H., Mirzaei, H. R., Sahebkar, A., Asemi, Z., & Mirzaei, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104353 · Cited by 188
STAT inhibitors for cancer therapy
Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-90 · Cited by 187
Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
Roufosse, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00049 · Cited by 187
Katagiri, K., Hattori, M., Minato, N., & Kinashi, T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.4.1001-1015.2002 · Cited by 182
Trial Watch: Toll-like receptor agonists for cancer therapy
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25238 · Cited by 180
The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma
Takanami, I., Takeuchi, K., & Giga, M. (2001) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2001.113026 · Cited by 174
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 173
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
Takeda, K., NAKAYAMA, M., Hayakawa, Y., Kojima, Y., Ikeda, H., Imai, N., Ogasawara, K., Okumura, K., Thomas, D. M., & Smyth, M. J. (2017) · Nature Communications · doi:10.1038/ncomms14607 · Cited by 171
Marié, I., Smith, E., Prakash, A., & Levy, D. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8803-8814.2000 · Cited by 170
Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis
Zhao, S., Wu, D., Wu, P., Wang, Z., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139598 · Cited by 164
Interaction between the Components of the Interferon γ Receptor Complex
Kotenko, S. V., Izotova, L. S., Pollack, B. P., Mariano, T. M., Donnelly, R. J., Muthukumaran, G., Cook, J. R., Garotta, G., Silvennoinen, O., Ihle, J. N., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.20915 · Cited by 164
Huang, G., Wu, X., Shi, L., Xu, X., Hua, Z., & Chen, X. (2016) · Scientific Reports · doi:10.1038/srep26524 · Cited by 157
Napabucasin: an update on the first-in-class cancer stemness inhibitor
Hubbard, J. M., & Grothey, A. (2017) · Drugs · doi:10.1007/s40265-017-0759-4 · Cited by 157
Prospects of IL-2 in Cancer Immunotherapy
Choudhry, H., Helmi, N. M., Abdulaal, W. H., Zeyadi, M., Zamzami, M. A., Wu, W., Mahmoud, M. M., Warsi, M. K., Rasool, M., & Jamal, M. S. (2018) · BioMed Research International · doi:10.1155/2018/9056173 · Cited by 155
Stover, D. G., del Alcazar, C. R. G., Brock, J. E., Guo, H., Overmoyer, B. A., Balko, J. M., Xu, Q., Bardia, A., Tolaney, S. M., Gelman, R. S., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0060-z · Cited by 154
Lu, C., Klement, J. D., Ibrahim, M. L., Xiao, W. L., Redd, P. S., Nayak-Kapoor, A., Zhou, G., & Liu, K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0635-8 · Cited by 154
Reprogramming of IL-10 Activity and Signaling by IFN-γ
Herrero, C., Hu, X., Li, W. P., Samuels, S., Sharif, M. N., Kotenko, S. V., & Ivashkiv, L. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5034 · Cited by 153
COX inhibitors and breast cancer
Mazhar, D., Ang, R., & Waxman, J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602942 · Cited by 146
Liu, L., Rich, B. E., Inobe, J., Chen, W., & Weiner, H. L. (1998) · International Immunology · doi:10.1093/intimm/10.8.1017 · Cited by 146
Bhatia, S., Miller, N. J., Lu, H., Longino, N. V., Ibrani, D., Shinohara, M. M., Byrd, D. R., Parvathaneni, U., Kulikauskas, R. M., ter Meulen, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0469 · Cited by 146
Ligand-Induced Assembly and Activation of the Gamma Interferon Receptor in Intact Cells
Bach, E. A., Tanner, J. W., Marsters, S., Ashkenazi, A., Aguet, M., Shaw, A. S., & Schreiber, R. D. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.6.3214 · Cited by 145
Mortara, L., Balza, E., Bruno, A., Poggi, A. D., Orecchia, P., & Carnemolla, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02905 · Cited by 144
The contribution of direct TLR signaling to T cell responses
Rahman, A. H., Taylor, D. K., & Turka, L. A. (2009) · Immunologic Research · doi:10.1007/s12026-009-8113-x · Cited by 143
CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance
Putz, E. M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., Straka, E., Rigler, D., Wallner, B., Jamieson, A. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.012 · Cited by 143
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Iribarren, K., Bloy, N., Buqué, A., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1088631 · Cited by 142
de Kruijf, E. M., Sajet, A., van Nes, J. G. H., Putter, H., Smit, V. T. H. B. M., Eagle, R. A., Jafferji, I., Trowsdale, J., Liefers, G., van de Velde, C. J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-24 · Cited by 141
New Function of Type I IFN: Induction of Autophagy
Schmeisser, H., Bekisz, J., & Zoon, K. C. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0128 · Cited by 140
Albacker, L. A., Wu, J., Smith, P. G., Warmuth, M., Stephens, P. J., Zhu, P., Yu, L., & Chmielecki, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176181 · Cited by 139
Hix, L. M., Karavitis, J., Khan, M. W., Shi, Y. H., Khazaie, K., & Zhang, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441402 · Cited by 138
Yang, M. H., Liu, J., Piao, C., Shao, J., & Du, J. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.144 · Cited by 134
Decker, T., Lew, D. J., & Darnell, J. E., Jr. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5147 · Cited by 134
A new look at T cell receptor signaling to nuclear factor-κB
Paul, S., & Schaefer, B. C. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.02.002 · Cited by 134
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population
Nielsen, C. M., Birgens, H., Nordestgaard, B. G., Kjær, L., & Bojesen, S. E. (2010) · Haematologica · doi:10.3324/haematol.2010.033191 · Cited by 131
Fine-Tuning of Type I Interferon Response by STAT3
Tsai, M.-H., Pai, L., & Lee, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01448 · Cited by 130
Jones, L., Broz, M. L., Ranger, J. J., Ozcelik, J., Ahn, R., Zuo, D., Ursini‐Siegel, J., Hallett, M. T., Krummel, M. F., & Muller, W. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2770 · Cited by 128
Activation of a CrkL-Stat5 Signaling Complex by Type I Interferons
Fish, E. N., Shahab Uddin, M. S., Korkmaz, M., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.571 · Cited by 127
Novel activators and small-molecule inhibitors of STAT3 in cancer
Yang, L., Lin, S., Xu, L., Lin, J., Zhao, C., & Huang, X. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.10.005 · Cited by 127
Schmitt, M. J., Philippidou, D., Reinsbach, S. E., Margue, C., Wienecke-Baldacchino, A. K., Nashan, D., Behrmann, I., & Kreis, S. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-41 · Cited by 123
Type I Interferons as Regulators of Human Antigen Presenting Cell Functions
Gessani, S., Conti, L., Cornò, M. D., & Belardelli, F. (2014) · Toxins · doi:10.3390/toxins6061696 · Cited by 119
STATs in NK-Cells: The Good, the Bad, and the Ugly
Gotthardt, D., & Sexl, V. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00694 · Cited by 118
Ning, S., Huye, L. E., & Pagano, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404260200 · Cited by 117
Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer
Walker, S. R., Xiang, M. H., & Frank, D. A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.010 · Cited by 117
IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression
Jing, N., Wang, Y., Yang, J. B., & Stark, G. R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714102115 · Cited by 116
Rhee, S. H., Jones, B. W., Toshchakov, V. Y., Vogel, S. N., & Fenton, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208633200 · Cited by 114
Role of let-7 family microRNA in breast cancer
Thammaiah, C. K., & Jayaram, S. (2016) · Non-coding RNA Research · doi:10.1016/j.ncrna.2016.10.003 · Cited by 114
Expression of STAT3 in Prostate Cancer Metastases
Don‐Doncow, N., Marginean, F. E., Coleman, I. M., Nelson, P. S., Ehrnström, R. A., Krzyzanowska, A., Morrissey, C. M., Hellsten, R., & Bjartell, A. S. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.018 · Cited by 112
Lü, L., Zhu, F., Zhang, M., Li, Y., Drennan, A. C., Kimpara, S., Rumball, I., Selzer, C., Cameron, H., Kellicut, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715118115 · Cited by 109
Hayakawa, F., Sugimoto, K., Harada, Y., Hashimoto, N., Ohi, N., Kurahashi, S., & Naoe, T. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.63 · Cited by 108
Jiang, M., Zhang, W., Liu, P.-P., Yu, W.-W., Liu, T., & Yu, J.-P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00070 · Cited by 106
Loss of STAT1 from Mouse Mammary Epithelium Results in an Increased Neu-Induced Tumor Burden
Klover, P. J., Muller, W. J., Robinson, G. W., Pfeiffer, R. M., Yamaji, D., & Hennighausen, L. G. (2010) · Neoplasia · doi:10.1593/neo.10716 · Cited by 104
The revival of CpG oligonucleotide-based cancer immunotherapies
Adamus, T., & Kortylewski, M. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73887 · Cited by 104
Zhao, H., Xu, R., Huang, X., Cheng, S.-M., Huang, M.-F., Yue, H., Wang, X., Zou, Y., Lü, A., & Liu, D. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00455 · Cited by 102
Liu, Y., Wang, X., Zeng, S., Zhang, X., Zhao, J., Zhang, X., Chen, X., Yang, W., Yang, Y., Dong, Z., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0959-0 · Cited by 99
Rodríguez, T., Méndez, R., Campo, A. D., Jiménez, P., Aptsiauri, N., Garrido, F., & Ruiz‐Cabello, F. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-34 · Cited by 98
Keskinen, P., Ronni, T., Matikainen, S., et al. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00258.x · Cited by 96
Demoulin, J., Roost, E. V., Stevens, M., Groner, B., & Renauld, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25855 · Cited by 96
Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
Berraondo, P., Etxeberría, I., Ponz‐Sarvisé, M., & Melero, I. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0381 · Cited by 96
Giroux, M., Schmidt, M., & Descoteaux, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4187 · Cited by 95
Rubio, D., Xu, R.-H., Remakus, S., Krouse, T. E., Truckenmiller, M. E., Thapa, R. J., Balachandran, S., Alcamı́, A., Norbury, C. C., & Sigal, L. J. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.04.015 · Cited by 94
Dill, E. A., Dillon, P. M., Bullock, T. N. J., & Mills, A. M. (2018) · Modern Pathology · doi:10.1038/s41379-018-0061-3 · Cited by 94
Wang, W., Yin, Y., Xu, L., Su, J., Huang, F., Wang, Y., Boor, P. P. C., Chen, K., Wang, W., Cao, W., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aah4248 · Cited by 93
Interferon Regulatory Factors in Hematopoietic Cell Differentiation and Immune Regulation
Battistini, A. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2009.0030 · Cited by 92
Romieu, R., Solis, M., Nardin, A., Goubau, D., Baron‐Bodo, V., Lin, R., Massie, B., Salcedo, M., & Hiscott, J. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1279 · Cited by 91
Zhou, J., Qu, Z., Sun, F., Han, L., Li, L., Yan, S., Stabile, L. P., Chen, L., Siegfried, J. M., & Xiao, G. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0073 · Cited by 91
Hahn, Y., Kim, S., Choi, B., Cho, K.-C., Bandu, R., Kim, K. P., Kim, D., Kim, W.-K., Park, J. S., Han, B. W., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23840-2 · Cited by 91
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression
Wen, L., Ding, K., Wang, Z.-R., Ding, C., Lei, S.-J., Liu, J.-P., Yin, C., Hu, P., Ding, J., Chen, W., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3896 · Cited by 90
Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Brockwell, N. K., Owen, K. L., Zanker, D. J., Spurling, A., Rautela, J., Duivenvoorden, H. M., Baschuk, N., Caramia, F., Loi, S., Darcy, P. K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0150 · Cited by 88
Self-citationMutations in the signal transducer and activator of transcription family of genes in cancer
Shahmarvand, N., Nagy, A., Shahryari, J., & Ohgami, R. S. (2018) · Cancer Science · doi:10.1111/cas.13525 · Cited by 86
Rautela, J., Baschuk, N., Slaney, C. Y., Jayatilleke, K. M., Xiao, K., Bidwell, B. N., Lucas, E. C., Hawkins, E. D., Lock, P., Wong, C. S. F., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0065 · Cited by 83
Self-citationSTAT1 signaling shields T cells from NK cell-mediated cytotoxicity
Kang, Y. H., Biswas, A., Field, M., & Snapper, S. B. (2019) · Nature Communications · doi:10.1038/s41467-019-08743-8 · Cited by 83
Tymoszuk, P., Charoentong, P., Hackl, H., Seeboeck, R., Müller‐Holzner, E., Trajanoski, Z., Obrist, P., Révillion-Carette, F., Peyrat, J., Fiegl, H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-257 · Cited by 81
Niu, G.-J., Xu, J., Yuan, W., Sun, J., Yang, M., Zhong-hua, H., Zhao, X., & Wang, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02392 · Cited by 81
STAT1 as a central mediator of IFNγ and TLR4 signal integration in vascular dysfunction
Sikorski, K., Chmielewski, S., Olejnik, A., Wesoły, J., Heemann, U. W., Baumann, M., & Bluyssen, H. A. R. (2012) · JAK-STAT · doi:10.4161/jkst.22469 · Cited by 74
Jadus, M., Irwin, M., Irwin, M., Horansky, R., Sekhon, S., Pepper, K. A., Kohn, D. B., & Wepsic, H. T. (1996) · Blood · doi:10.1182/blood.v87.12.5232.bloodjournal87125232 · Cited by 73
Medina‐Echeverz, J., Haile, L. A., Zhao, F., Gamrekelashvili, J., Ma, C., Métais, J., Dunbar, C. E., Kapoor, V., Manns, M. P., Korangy, F., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201444497 · Cited by 73
Wu, Y., Xu, J., Xu, J., Zheng, W., Chen, Q., & Jiao, D. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8477 · Cited by 73
JAK / STAT signaling in regulation of innate lymphoid cells: The gods before the guardians
Stabile, H., Scarno, G., Fionda, C., Gismondi, A., Santoni, A., Gadina, M., & Sciumè, G. (2018) · Immunological Reviews · doi:10.1111/imr.12705 · Cited by 73
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Adipose tissue and insulin resistance in obese
Ahmed, B., Sultana, R., & Greene, M. W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111315 · Cited by 1,047
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 569
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Metadata
- Authors
- Owen, K. L., Brockwell, N. K., & Parker, B. S.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-12-12
- Volume
- 11
- Issue
- 12
- Pages
- 2002
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2996238888
- Cited by
- 714
- References
- 229
- FWCI
- 25.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.